Zydus Lifesciences gets final approval from USFDA for Varenicline Tablets

13 Jun 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Varenicline Tablets, 0.5 mg and 1 mg (USRLD: Chantix Tablets). The product will be launched shortly. Varenicline tablets is indicated to treat smoking addiction. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. 

Varenicline Tablets, 0.5 mg and 1 mg had annual sales of $501 million in the United States (IQVIA MAT March 2023). The group now has 374 approvals and has so far filed over 442 (as of March 31, 2023) ANDAs since the commencement of the filing process in FY 2003-04

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. 

Zydus Lifesciences Share Price

872.95 -8.15 (-0.92%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×